Honedra® (CLBS12) autologous CD34+ cells improve outcomes in patients with Buerger’s disease
Atsuhiko Kawamoto(Northwestern University), Douglas W. Losordo(MACOM (United States)), Shuzo Kobayashi(Shonan Kamakura General Hospital), J. Wang(Neostem (United States)), William K. Sietsema(Neostem (United States)), Nobuyoshi Azuma(Asahikawa Medical University), Yasuyuki Fujita(Sapporo University), Kazuki Tobita(Shonan Kamakura General Hospital), Masato Nakamura(Toho University), Junichi Yamaguchi(Tokyo Women's Medical University), Yutaka Furukawa(Kobe City Medical Center General Hospital), Gen Takagi(University of Würzburg), Amane Kozuki(Saiseikai Nakatsu Hospital), Hiroshi Takagi(Nara Institute of Science and Technology), Naotaka Murata(Tokyo Medical University Hospital), H. Yokoi, H. Matsumura(Tokyo Medical University Hospital), Isao Kitano(Shinko Hospital), M. Furukawa, Wataru Shimizu(Nippon Medical School Hospital), R.L. Bartel(Neostem (United States)), Hideaki Obara(Keio University)
Cited by 0
Related Papers
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
|European Heart Journal|2018|2.1k
Global vascular guidelines on the management of chronic limb-threatening ischemia
|Journal of Vascular Surgery|2019|1.9k
Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia
|European Journal of Vascular and Endovascular Surgery|2019|1.5k
Gene Therapy for Myocardial Angiogenesis
|Circulation|1998|993